Q-omics provides the consensus-scored NTAN1 profile across patient tissues and cancer cell-line models. NTAN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NTAN1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NTAN1 protein abundance shows 21,678 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where NTAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTAN1 survival associations across molecular data types. NTAN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTAN1 RNA expression–survival associations across cancer types. High NTAN1 expression shows unfavorable associations in ACC, STAD, UVM, LGG and KIRP, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NTAN1 RNA expression.
This table summarizes NTAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NTAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTAN1 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher NTAN1 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p < 0.001).
This table shows molecular features associated with NTAN1 in patient tissues and cancer cell lines. In patient samples, NTAN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
